Navigation Links
Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Date:2/27/2008

PITTSBURGH, Feb. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension. The companies have agreed that Forest will assume Mylan's commercial rights for Bystolic in the U.S. and Canada including, but not limited to, the elimination of Mylan's option to co-promote the product. Forest will be responsible for all future Bystolic development expenses as well as all sales and marketing expenses for the product.

Under the terms of this amendment, Forest Laboratories Holdings, Ltd. (Ireland) will make a one-time cash payment of $370 million to Mylan. Forest will continue to pay Mylan its contractual royalties for three years, through calendar 2010.

Robert J. Coury, Vice Chairman and CEO of Mylan, commented: "We are very proud of the role Mylan has played to date in Bystolic's development and commercialization in the U.S. and believe that today's agreement with Forest is evidence of the value we have created through this product. Today's announcement is just one of the many initiatives we have announced to enhance our strategic focus and ensure we are ideally positioned to maximize the significant opportunities of our world leading generics assets."

About Bystolic

'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... A new infographic compiles useful information about ... to learn how Apple’s new framework can change the ... ideal since Apple made Research Kit available ... framework for developing medical research apps that Apple announced ... to collect secure clinical data and communicate via subjects’ ...
(Date:4/16/2015)... 16, 2015 Avelas Biosciences, an in ... surgeries, announced today that it has initiated a Phase ... in women with primary, non-recurrent breast cancer undergoing surgery. ... the addition of Steven Chen , M.D., as ... label, dose escalation study will enroll up to 39 ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... CAMBRIDGE, England, October 12 Crescendo Biologics,("Crescendo") today ... to advance the development of its fragment antibody technology,platforms. ... Paris-based,venture capital firm, with Aitua, Avlar BioVentures and the ... Crescendo brings together highly innovative in vivo and in ...
... , SAN FRANCISCO, Oct. 12 Dr. Michael ... implant inventor, brain plasticity expert and ... Medicine (IOM) today in Washington, D.C. Also a member of ... a small group of scientists and doctors in the U.S. ...
... ANA, Calif., Oct. 12 Selexis SA ("Selexis") and ... present results of a recent collaborative effort combining the ... IS CHO Culture System, demonstrating the rapid production of ... cell lines. Irvine and Selexis will jointly present ...
Cached Biology Technology:Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners 2Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners 3Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners 4Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3Irvine Scientific and Selexis to Announce Results of Successful Collaboration 2
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... The 2007 American College of Neuropsychopharmacology Annual Meeting will ... from the worlds leading scientists. Presentations include innovative ... disorder, autism and addiction. SELECTED PANELS ... Cancer and Schizophrenia A series of studies elucidates evidence ...
... FOR IMMEDIATE RELEASE First identification of blood on ... Scientists in France are reporting for the first time that ... once the source of almost half the worlds gold ... their works of art. In a study scheduled for the ...
... numerals that is superior to that of human adults, ... Biology, a publication of Cell Press. There are ... humans are superior to chimpanzees in all cognitive functions, ... imagine that chimpanzeesyoung chimpanzees at the age of fivehave ...
Cached Biology News:New studies on schizophrenia, depression, trauma and autism highlight annual meeting 2New studies on schizophrenia, depression, trauma and autism highlight annual meeting 3American Chemical Society's Weekly PressPac -- Nov. 28, 2007 2American Chemical Society's Weekly PressPac -- Nov. 28, 2007 3American Chemical Society's Weekly PressPac -- Nov. 28, 2007 4American Chemical Society's Weekly PressPac -- Nov. 28, 2007 5American Chemical Society's Weekly PressPac -- Nov. 28, 2007 6American Chemical Society's Weekly PressPac -- Nov. 28, 2007 7American Chemical Society's Weekly PressPac -- Nov. 28, 2007 8Young chimps top adult humans in numerical memory 2
... The binding specificity and signaling of ... known to be modified by alternative splicing--which ... GPCR SpliceArrays you can perform a classical ... detect the different alternatively spliced forms of ...
... color screen, without Camera • ... 8.0 mega pixel resolution. It is computer free ... image from large 5.6" TFT color liquid crystal ... to capture image for fluorescent gels, colorimetric gels, ...
... signaling of the members of the GPCR ... alternative splicing--which has important implications for drug ... a classical expression profiling and at the ... forms of the gene that are expressed ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
Biology Products: